{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T00:15:45Z","timestamp":1772151345005,"version":"3.50.1"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pharm Res"],"published-print":{"date-parts":[[2025,6]]},"DOI":"10.1007\/s11095-025-03881-9","type":"journal-article","created":{"date-parts":[[2025,6,13]],"date-time":"2025-06-13T16:29:54Z","timestamp":1749832194000},"page":"1021-1033","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Controlling Gastric Delivery of a GIP\/GLP1 Peptide in Monkeys by Mucoadhesive SNAC Tablets"],"prefix":"10.1007","volume":"42","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8391-8404","authenticated-orcid":false,"given":"Huyen","family":"Tran","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jennifer","family":"Martin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mridula","family":"Dogra","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jenna","family":"Walker","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Donald","family":"Risley","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aktham","family":"Aburub","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,6,13]]},"reference":[{"issue":"4","key":"3881_CR1","doi-asserted-by":"publisher","first-page":"1097","DOI":"10.1016\/j.drudis.2021.01.020","volume":"26","author":"AT Zizzari","year":"2021","unstructured":"Zizzari AT, Pliatsika D, Gall FM, Fischer T, Riedl R. New perspectives in oral peptide delivery. Drug Discov Today. 2021;26(4):1097\u2013105.","journal-title":"Drug Discov Today"},{"issue":"2","key":"3881_CR2","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1080\/17425247.2022.2051476","volume":"19","author":"H Tran","year":"2022","unstructured":"Tran H, ElSayed MEH. Progress and limitations of oral peptide delivery as a potentially transformative therapy. Expert Opin Drug Deliv. 2022;19(2):163\u201378.","journal-title":"Expert Opin Drug Deliv"},{"issue":"10","key":"3881_CR3","doi-asserted-by":"publisher","first-page":"2555","DOI":"10.1007\/s11095-022-03372-1","volume":"39","author":"H Tran","year":"2022","unstructured":"Tran H, Patel PJ, Aburub A, Sperry A, Estwick S, ElSayed MEH, Mannan AD. Identification of a Multi-Component Formulation for Intestinal Delivery of a GLP-1\/Glucagon Co-agonist Peptide. Pharm Res. 2022;39(10):2555\u201367.","journal-title":"Pharm Res"},{"issue":"4","key":"3881_CR4","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1038\/s41573-019-0053-0","volume":"19","author":"DJ Drucker","year":"2020","unstructured":"Drucker DJ. Advances in oral peptide therapeutics. Nat Rev Drug Discov. 2020;19(4):277\u201389.","journal-title":"Nat Rev Drug Discov"},{"issue":"2","key":"3881_CR5","doi-asserted-by":"publisher","first-page":"929","DOI":"10.1021\/acs.molpharmaceut.2c00443","volume":"20","author":"H Tran","year":"2023","unstructured":"Tran H, Aihara E, Mohammed FA, Qu H, Riley A, Su Y, et al. In Vivo Mechanism of Action of Sodium Caprate for Improving the Intestinal Absorption of a GLP1\/GIP Coagonist Peptide. Mol Pharm. 2023;20(2):929\u201341.","journal-title":"Mol Pharm"},{"issue":"10","key":"3881_CR6","doi-asserted-by":"publisher","first-page":"1501","DOI":"10.1080\/17425247.2021.1942838","volume":"18","author":"DJ Brayden","year":"2021","unstructured":"Brayden DJ, Maher S. Transient Permeation Enhancer(R) (TPE(R)) technology for oral delivery of octreotide: a technological evaluation. Expert Opin Drug Deliv. 2021;18(10):1501\u201312.","journal-title":"Expert Opin Drug Deliv"},{"issue":"467","key":"3881_CR7","doi-asserted-by":"publisher","first-page":"eaar7047","DOI":"10.1126\/scitranslmed.aar7047","volume":"10","author":"ST Buckley","year":"2018","unstructured":"Buckley ST, Baekdal TA, Vegge A, Maarbjerg SJ, Pyke C, Ahnfelt-Ronne J, et al. Transcellular stomach absorption of a derivatized glucagon-like peptide-1 receptor agonist. Sci Transl Med. 2018;10(467):eaar7047.","journal-title":"Sci Transl Med."},{"issue":"8","key":"3881_CR8","doi-asserted-by":"publisher","first-page":"2010","DOI":"10.1007\/s11095-014-1303-9","volume":"31","author":"S Tuvia","year":"2014","unstructured":"Tuvia S, Pelled D, Marom K, Salama P, Levin-Arama M, Karmeli I, et al. A novel suspension formulation enhances intestinal absorption of macromolecules via transient and reversible transport mechanisms. Pharm Res. 2014;31(8):2010\u201321.","journal-title":"Pharm Res"},{"issue":"Pt B","key":"3881_CR9","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1016\/j.addr.2016.06.005","volume":"106","author":"S Maher","year":"2016","unstructured":"Maher S, Mrsny RJ, Brayden DJ. Intestinal permeation enhancers for oral peptide delivery. Adv Drug Deliv Rev. 2016;106(Pt B):277\u2013319.","journal-title":"Adv Drug Deliv Rev"},{"key":"3881_CR10","doi-asserted-by":"publisher","first-page":"784","DOI":"10.1016\/j.jconrel.2021.09.002","volume":"338","author":"P Tyagi","year":"2021","unstructured":"Tyagi P, Trivedi R, Pechenov S, Patel C, Revell J, Wills S, et al. Targeted oral peptide delivery using multi-unit particulates: Drug and permeation enhancer layering approach. J Control Release. 2021;338:784\u201391.","journal-title":"J Control Release"},{"key":"3881_CR11","unstructured":"Pechenov S, Tyagi P, Subramony JA,\u00a0MedImmune LLC. Oral delivery of GLP-1 peptide analogs. Patent WO 2019 (087083 A2)."},{"key":"3881_CR12","doi-asserted-by":"publisher","first-page":"113925","DOI":"10.1016\/j.addr.2021.113925","volume":"177","author":"S Maher","year":"2021","unstructured":"Maher S, Brayden DJ. Formulation strategies to improve the efficacy of intestinal permeation enhancers. Adv Drug Deliv Rev. 2021;177:113925.","journal-title":"Adv Drug Deliv Rev"},{"issue":"3","key":"3881_CR13","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1016\/j.ejpb.2008.09.028","volume":"71","author":"GP Andrews","year":"2009","unstructured":"Andrews GP, Laverty TP, Jones DS. Mucoadhesive polymeric platforms for controlled drug delivery. Eur J Pharm Biopharm. 2009;71(3):505\u201318.","journal-title":"Eur J Pharm Biopharm"},{"issue":"5","key":"3881_CR14","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1016\/j.jdent.2008.01.014","volume":"36","author":"MA Zaman","year":"2008","unstructured":"Zaman MA, Martin GP, Rees GD. Mucoadhesion, hydration and rheological properties of non-aqueous delivery systems (NADS) for the oral cavity. J Dent. 2008;36(5):351\u20139.","journal-title":"J Dent"},{"key":"3881_CR15","doi-asserted-by":"publisher","first-page":"123680","DOI":"10.1016\/j.ijpharm.2023.123680","volume":"650","author":"H Tran","year":"2024","unstructured":"Tran H, Dogra M, Huang S, Aihara E, ElSayed M, Aburub A. Development and evaluation of C10 and SNAC erodible tablets for gastric delivery of a GIP\/GLP1 peptide in monkeys. Int J Pharm. 2024;650:123680.","journal-title":"Int J Pharm"},{"issue":"5","key":"3881_CR16","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1002\/cpdd.938","volume":"10","author":"TA Baekdal","year":"2021","unstructured":"Baekdal TA, Donsmark M, Hartoft-Nielsen ML, Sondergaard FL, Connor A. Relationship Between Oral Semaglutide Tablet Erosion and Pharmacokinetics: A Pharmacoscintigraphic Study. Clin Pharmacol Drug Dev. 2021;10(5):453\u201362.","journal-title":"Clin Pharmacol Drug Dev"},{"key":"3881_CR17","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejps.2020.105509","volume":"154","author":"S Fattah","year":"2020","unstructured":"Fattah S, Ismaiel M, Murphy B, Rulikowska A, Frias JM, Winter DC, Brayden DJ. Salcaprozate sodium (SNAC) enhances permeability of octreotide across isolated rat and human intestinal epithelial mucosae in Ussing chambers. Eur J Pharm Sci. 2020;154: 105509.","journal-title":"Eur J Pharm Sci"},{"key":"3881_CR18","unstructured":"Milata Mary Abraham JA-F, Robert Andrew Brown, Over Cabrera, Tamer Cuskun, Robert Chadwick Cummins, Mohamed EISayed Hamed Elsayed, Hongchang Qu, James Lincoln Wallis, Amita Datta-Mannan, Xianyin Lai. GIP\/GLP1 Co-agonist Compounds. US patent. 2021;US 11,084,861 B2."},{"key":"3881_CR19","doi-asserted-by":"publisher","first-page":"504","DOI":"10.1016\/j.jconrel.2022.09.024","volume":"351","author":"R Kumar","year":"2022","unstructured":"Kumar R, Islam T, Nurunnabi M. Mucoadhesive carriers for oral drug delivery. J Control Release. 2022;351:504\u201359.","journal-title":"J Control Release"},{"key":"3881_CR20","doi-asserted-by":"publisher","first-page":"201","DOI":"10.18433\/jpps32705","volume":"25","author":"S Golshani","year":"2022","unstructured":"Golshani S, Vatanara A, Amin M. Recent Advances in Oral Mucoadhesive Drug Delivery. J Pharm Pharm Sci. 2022;25:201\u201317.","journal-title":"J Pharm Pharm Sci"},{"issue":"3","key":"3881_CR21","doi-asserted-by":"publisher","first-page":"E77","DOI":"10.1208\/pt0803077","volume":"8","author":"VM Patel","year":"2007","unstructured":"Patel VM, Prajapati BG, Patel HV, Patel KM. Mucoadhesive bilayer tablets of propranolol hydrochloride. AAPS PharmSciTech. 2007;8(3):E77.","journal-title":"AAPS PharmSciTech"},{"issue":"1","key":"3881_CR22","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/j.jconrel.2004.04.013","volume":"98","author":"K Whitehead","year":"2004","unstructured":"Whitehead K, Shen Z, Mitragotri S. Oral delivery of macromolecules using intestinal patches: applications for insulin delivery. J Control Release. 2004;98(1):37\u201345.","journal-title":"J Control Release"},{"issue":"4","key":"3881_CR23","doi-asserted-by":"publisher","first-page":"104340","DOI":"10.1016\/j.drudis.2025.104340","volume":"30","author":"H Omidian","year":"2025","unstructured":"Omidian H. Gastroretentive drug delivery systems: A holy grail in oral delivery. Drug Discov Today. 2025;30(4):104340.","journal-title":"Drug Discov Today"},{"key":"3881_CR24","doi-asserted-by":"publisher","first-page":"792","DOI":"10.1016\/j.jconrel.2022.12.011","volume":"353","author":"S Berg","year":"2023","unstructured":"Berg S, Uggla T, Antonsson M, Nunes SF, Englund M, Rosengren L, et al. Evaluation in pig of an intestinal administration device for oral peptide delivery. J Control Release. 2023;353:792\u2013801.","journal-title":"J Control Release"}],"container-title":["Pharmaceutical Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11095-025-03881-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11095-025-03881-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11095-025-03881-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,2]],"date-time":"2025-07-02T14:22:18Z","timestamp":1751466138000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11095-025-03881-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6]]},"references-count":24,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,6]]}},"alternative-id":["3881"],"URL":"https:\/\/doi.org\/10.1007\/s11095-025-03881-9","relation":{},"ISSN":["0724-8741","1573-904X"],"issn-type":[{"value":"0724-8741","type":"print"},{"value":"1573-904X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6]]},"assertion":[{"value":"29 January 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 June 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 June 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"At the time the work in this publication was performed, all authors were employees of Eli Lilly and Company. The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}